Synjardy

Congestive Heart Failure, Physical Activity, Monotherapy + 8 more

Treatment

6 FDA approvals

20 Active Studies for Synjardy

What is Synjardy

Empagliflozin

The Generic name of this drug

Treatment Summary

Metformin is a medication used to treat type 2 diabetes. It is the first-line drug of choice for managing type 2 diabetes and is taken by more than 120 million people around the world. Metformin lowers blood sugar levels without causing hypoglycemia, increases insulin sensitivity, and leads to modest weight loss. It was first approved in Canada in 1972 and in the United States in 1995. Metformin is available in regular and extended-release form.

Jardiance

is the brand name

image of different drug pills on a surface

Synjardy Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Jardiance

Empagliflozin

2014

24

Approved as Treatment by the FDA

Empagliflozin, also called Jardiance, is approved by the FDA for 6 uses including Type 2 Diabetes Mellitus and Physical Activity .

Type 2 Diabetes Mellitus

Used to treat Type 2 Diabetes Mellitus in combination with Metformin

Physical Activity

Used to treat Exercise in combination with Metformin

Type 2 Diabetes

Used to treat Type 2 Diabetes Mellitus in combination with Metformin

Diet

Used to treat Diet in combination with Metformin

Cardiovascular Diseases

Cardiovascular Mortality

Effectiveness

How Synjardy Affects Patients

Insulin is a hormone that helps control the amount of sugar in the blood. People with Type II diabetes have a decreased sensitivity to insulin, which means their pancreas cannot keep up with regulating their sugar levels. Metformin works to reduce the amount of sugar produced by the liver and absorbed by the intestines, as well as increase the body's sensitivity to insulin. In a clinical trial, people taking Metformin had decreased fasting blood sugar levels by an average of 59 mg/dL, while those taking a placebo had increased levels by 6.3 mg/dL. Metformin also decreased HbA1c by 1

How Synjardy works in the body

Metformin works in several ways to reduce blood glucose levels. It decreases the amount of glucose produced in the liver, decreases the amount of glucose absorbed from food in the intestines, and makes cells more sensitive to insulin. Metformin enters liver cells through a transporter called OCT1, and accumulates in the mitochondria. It blocks the production of energy in the mitochondria, turning on an enzyme called AMPK. This helps to decrease fat production and increase fat burning, as well as reduce glucose production in the liver. In the intestines, metformin increases anaerobic glucose metabolism, leading to less net glucose uptake and

When to interrupt dosage

The suggested dose of Synjardy is contingent upon the recognized disorder, including Diet, inadequate response to metformin and Diabetic Ketoacidosis. The quantity differs, in line with the methodology of delivery (e.g. Oral or Tablet - Oral) listed in the table below.

Condition

Dosage

Administration

Cardiovascular Diseases

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Type 2 Diabetes

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Diet

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Cardiovascular Mortality

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Heart Failure

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Therapeutic procedure

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Ejection fraction decreased

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Hospitalizations

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Congestive Heart Failure

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Physical Activity

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Monotherapy

10.0 mg, 25.0 mg, , 5.0 mg, 12.5 mg

Tablet, Tablet - Oral, Oral, , Tablet, film coated, Tablet, film coated - Oral, Tablet, extended release - Oral, Tablet, extended release

Warnings

Synjardy Contraindications

Condition

Risk Level

Notes

Kidney Failure

Do Not Combine

Renal Dialysis

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Empagliflozin may interact with Pulse Frequency

There are 20 known major drug interactions with Synjardy.

Common Synjardy Drug Interactions

Drug Name

Risk Level

Description

Acetazolamide

Minor

Empagliflozin may increase the diuretic activities of Acetazolamide.

Ambrisentan

Minor

Empagliflozin may increase the hypotensive activities of Ambrisentan.

Amiloride

Minor

Empagliflozin may increase the diuretic activities of Amiloride.

Angiotensin 1-7

Minor

Empagliflozin may increase the hypotensive activities of Angiotensin 1-7.

Azosemide

Minor

Empagliflozin may increase the diuretic activities of Azosemide.

Synjardy Toxicity & Overdose Risk

The toxic dose of metformin in rats is 1000mg/kg when taken orally, 500mg/kg when given through the abdomen, and 300mg/kg when injected under the skin. The toxic dose in mice is 1450mg/kg orally, 420mg/kg through the abdomen, and 225mg/kg when injected under the skin. Taking too much metformin can lead to lactic acidosis, a serious condition where too much acid builds up in the blood. Risk factors for lactic acidosis include kidney problems, being over 65 years old, taking certain medications, drinking too much alcohol, or having liver disease

image of a doctor in a lab doing drug, clinical research

Synjardy Novel Uses: Which Conditions Have a Clinical Trial Featuring Synjardy?

346 active trials are assessing the potential of Synjardy in treating Type 2 Diabetes, Type 1 Diabetes and inadequate response to Metformin therapy.

Condition

Clinical Trials

Trial Phases

Type 2 Diabetes

184 Actively Recruiting

Not Applicable, Phase 2, Phase 4, Phase 1, Early Phase 1, Phase 3

Cardiovascular Diseases

0 Actively Recruiting

Congestive Heart Failure

181 Actively Recruiting

Not Applicable, Phase 1, Early Phase 1, Phase 2, Phase 3, Phase 4

Hospitalizations

2 Actively Recruiting

Not Applicable

Monotherapy

1 Actively Recruiting

Phase 1, Phase 2

Heart Failure

0 Actively Recruiting

Diet

5 Actively Recruiting

Not Applicable, Phase 1

Therapeutic procedure

0 Actively Recruiting

Ejection fraction decreased

0 Actively Recruiting

Physical Activity

30 Actively Recruiting

Not Applicable, Phase 2

Cardiovascular Mortality

0 Actively Recruiting

Synjardy Reviews: What are patients saying about Synjardy?

5

Patient Review

10/17/2018

Synjardy for Type 2 Diabetes Mellitus

Synjardy has been great for me. I brought my A1C down from 10.6 to 6.0 in a year, and experienced zero negative side effects.

4

Patient Review

4/17/2016

Synjardy for Type 2 Diabetes Mellitus

4

Patient Review

11/9/2017

Synjardy for Type 2 Diabetes Mellitus

2.3

Patient Review

1/30/2019

Synjardy for Type 2 Diabetes Mellitus

My A1C rose from 6.5 to 8.7 after my doctor switched me from Farxiga to Synjardy. I found the latter drug much less effective than the former.

2

Patient Review

9/4/2018

Synjardy for Type 2 Diabetes Mellitus

I unfortunately got a yeast infection from this medication.

1.7

Patient Review

5/12/2019

Synjardy for Type 2 Diabetes Mellitus

Thirst, yeast infection, and constant trips to the bathroom are all unfortunately common side effects of this medication. I've been taking it for five months now and have had to deal with a lot of discomfort as a result.

1

Patient Review

9/9/2018

Synjardy for Type 2 Diabetes Mellitus

I was worried from the start with this prescription. My blood sugar shot up, and even when I increased the dose as directed, it didn't seem to be effective.

1

Patient Review

9/8/2021

Synjardy for Type 2 Diabetes Mellitus

I was in a lot of pain after injuring my knee and was prescribed Synjardy. However, this medication caused me more pain and fatigue than the original injury. I stopped taking it and felt better the next day.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about synjardy

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Synjardy used for?

"This medication is a combination of 2 drugs: empagliflozin and metformin. It is used with a proper diet and exercise program to lower blood sugar in people with type 2 diabetes. Controlling blood sugar helps prevent kidney damage, blindness, nerve problems, loss of limbs, and sexual function problems."

Answered by AI

What is the side effects of Synjardy?

"Some possible causes of these symptoms include low blood sugar, a urinary tract infection, a stuffy or runny nose and sore throat, yeast infections in females, diarrhea, nausea or vomiting, gas, stomach discomfort, indigestion, weakness, or a headache."

Answered by AI

What is the difference between Synjardy and metformin?

"Synjardy contains both metformin and the drug empagliflozin. Metformin lowers blood sugar levels through several mechanisms, and the addition of empagliflozin provides additional blood sugar lowering effects."

Answered by AI

Are Jardiance and Synjardy the same thing?

"Jardiance is a medication used to treat type 2 diabetes. It is available as a standalone tablet or as a combination tablet with metformin. The medication works by helping the body to better use insulin. Side effects may include nausea, diarrhea, and headaches. Jardiance is a brand-name medication and costs can vary depending on insurance coverage."

Answered by AI

Clinical Trials for Synjardy

Image of University of Cincinnati Medical Center in Cincinnati, United States.

Continuous Glucose Monitoring for Type 2 Diabetes

18+
All Sexes
Cincinnati, OH

The TRANSITION-CGM trial will evaluate whether starting continuous glucose monitoring (CGM) before hospital discharge improves blood glucose control in adults with type 2 diabetes compared with usual care using finger-stick blood glucose checks. The study focuses on the transition from hospital to home, when patients may face changes in diabetes medications and challenges managing their blood glucose levels. This single-center, randomized controlled trial will enroll approximately 218 adults with type 2 diabetes, a hemoglobin A1c (HbA1c) 9% and above, and treatment with insulin and/or oral diabetes medications. Participants will be recruited during hospitalization and must be expected to return home after discharge. People already using a CGM will not be eligible. Participants will be randomly assigned in equal numbers to one of two groups. The CGM group will start using a continuous glucose monitor before discharge and receive device training and written instructions. The usual-care group will continue finger-stick blood glucose monitoring and receive standard discharge education. Both groups will receive assistance with outpatient diabetes follow-up. Diabetes medications will be managed by treating clinicians according to usual clinical practice. Participants will be followed for approximately 12 weeks after discharge, with an early follow-up encounter and a final assessment at 12 weeks. The primary outcome is HbA1c at 12 weeks, a blood test that reflects average blood glucose levels over approximately three months. Secondary outcomes include diabetes-related hospitalizations and episodes of low blood sugar. Additional exploratory measures include CGM use, follow-up attendance, patient-reported experiences, and time spent within the target glucose range when CGM data are available. The study will determine whether initiating CGM during hospitalization can improve glycemic control after discharge and provide preliminary evidence about its effects on diabetes-related hospitalizations and hypoglycemia.

Waitlist Available
Has No Placebo

University of Cincinnati Medical Center

Arunab H Mehta, MD, MEd

Have you considered Synjardy clinical trials?

We made a collection of clinical trials featuring Synjardy, we think they might fit your search criteria.
Go to Trials
Image of Penn Medicine, 3535 Market St. in Philadelphia, United States.

Financial Counseling and Health Reviews for Chronic Illness Management

18+
All Sexes
Philadelphia, PA

Among adults with chronic illnesses like hypertension, diabetes, or HIV, adherence to daily oral medications is essential but often below 50%. Why do medication adherence and preventive health service engagement remain stubbornly low? Scarcity theory offers a novel explanation in the context of poverty. It posits that economic hardship imposes a cognitive burden that shifts attention from long-term goals to immediate needs, reduces future orientation (the relative value placed on immediate vs. future outcomes), and limits mental bandwidth (the cognitive resources needed for decisions), thus undermining behaviors like daily medication adherence and service engagement. To address these gaps, the study's objective is to rigorously test whether and how economic scarcity affects medication adherence and preventive service uptake among older adults with chronic disease, leveraging the naturally occurring monthly fluctuation in scarcity created by the Supplemental Nutrition Assistance Program (SNAP) benefit cycle as a natural experiment. There are three aims: 1. Daily medication adherence will be measured objectively for four months with wireless electronic pill bottle caps (CleverCaps). The investigators will test whether, when, and by how much adherence changes as scarcity fluctuates during the SNAP benefit cycle. 2. The investigators will conduct two easily implementable RCTs to test whether scarcity affects participants' engagement with beneficial services requiring navigation of administrative burdens. In one trial, participants will be randomized to receive an invitation during either a high- or low- scarcity period (i.e., before vs. after SNAP receipt) to a personalized preventive health review that identifies gaps in US Preventive Services Task Force Grade A/B recommendations. In the second, participants will be invited to free financial counseling provided by the City of Philadelphia during a high- or low-scarcity period. The investigators hypothesize invitation response rates will be \>15% higher during low-scarcity periods. 3. Potential mechanisms that link scarcity with health behaviors will be examined by randomizing timing of validated measures of mental bandwidth and future orientation during a period of high- or low-scarcity (i.e., before vs. after SNAP receipt). The investigators hypothesize that there will be differences in several measures between participants who are randomly assessed during high- vs. low-scarcity periods (i.e. before vs. after SNAP receipt). Impact: Demonstrating that scarcity helps to explain low medication adherence and beneficial health-related service uptake can inform patient-centered adherence interventions, clinical care-delivery approaches, health-system strategies, and public health approaches to improve these health behaviors and promote healthy aging.

Waitlist Available
Has No Placebo

Penn Medicine, 3535 Market St.

Have you considered Synjardy clinical trials?

We made a collection of clinical trials featuring Synjardy, we think they might fit your search criteria.
Go to Trials
Image of University of Colorado Anschutz in Denver, United States.

HEROIC Program for Heart Failure

18+
All Sexes
Denver, CO

This study will test the mechanisms of a multi-component, nurse-led, primary palliative care intervention, HEart failure Resilience Intervention for Caregivers (HEROIC) to improve caregiver mental well-being, patient health-related quality of life and unplanned acute care in the setting of advanced heart failure. The investigators will conduct a multi-site, randomized controlled trial to test proposed mechanisms of action in a large sample (N=500) of persons with heart failure and the caregivers. The investigators will also examine variation in response to HEROIC components by heart failure subgroup (ventricular assist device, heart transplant or medically managed heart failure).

Phase 2
Waitlist Available

University of Colorado Anschutz (+1 Sites)

Martha Abshire Saylor, PhD, RN

Image of Lake Havasu Unified School District in Lake Havasu City, United States.

Nutrition and Fitness Program for Schoolchildren's Health

9 - 14
All Sexes
Lake Havasu City, AZ

The goal of this clinical trial is to learn if a school-based intervention, Operation ToneUp, can improve nutrition knowledge, fitness, and blood pressure in schoolchildren enrolled in grades 3-6. The main questions it aims to answer are: 1. Do students participating in the intervention show improved fitness, measured by upper body strength, core strength, and cardiovascular endurance? 2. Do students participating in the intervention show improved nutrition knowledge, measured by self-report? 3. Do students participating in the intervention show improved blood pressure, measured by blood pressure cuff? Researchers will compare students participating in the intervention to students at comparison schools to see if fitness, nutrition knowledge, and blood pressure differ. Participants in the intervention arm will complete two 20-minute web-based sessions focused on nutrition and fitness during class time. Participants in the comparison arm will not be exposed to Operation ToneUp. All participants will engage in pre- and post- testing including: * PE-teacher assessed push-ups, curl-ups, and PACER test * online self-reported nutrition knowledge assessments * nurse-recorded blood pressure

Waitlist Available
Has No Placebo

Lake Havasu Unified School District

Allison Poulos, PhD

Have you considered Synjardy clinical trials?

We made a collection of clinical trials featuring Synjardy, we think they might fit your search criteria.
Go to Trials